Specialised Therapeutics, Orlando, FL (2026)

03/30/2026

𝗟𝗮𝘀𝘁 𝘄𝗲𝗲𝗸𝗲𝗻𝗱, 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝘄𝗮𝘀 𝗽𝗿𝗼𝘂𝗱 𝘁𝗼 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝘁𝗵𝗲 𝗟𝘆𝗺𝗽𝗵𝗼𝗺𝗮 𝗔𝘂𝘀𝘁𝗿𝗮𝗹𝗶𝗮 𝗛𝗲𝗮𝗹𝘁𝗵 𝗣𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗦𝘆𝗱𝗻𝗲𝘆.

It was a valuable opportunity for our team to connect with nurses, allied health professionals and multidisciplinary healthcare teams from across Australia who are dedicated to improving outcomes for patients affected by lymphoma.

At Specialised Therapeutics, we remain committed to supporting the haematology community through our growing portfolio and our ongoing work to bring innovative therapies to patients across Australia and the Asia-Pacific region.

Thank you to the organisers and healthcare professionals whose work continues to make a meaningful difference for patients and their families.

12/09/2025

𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗶𝘀 𝗰𝗼𝗺𝗺𝗶𝘁𝘁𝗲𝗱 𝘁𝗼 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗵𝗮𝗲𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝘆 𝗯𝘆 𝗯𝗿𝗶𝗻𝗴𝗶𝗻𝗴 𝗽𝗶𝘃𝗼𝘁𝗮𝗹 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝘁𝗼 𝘁𝗵𝗲 𝗴𝗹𝗼𝗯𝗮𝗹 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆.

This year marks a significant period for Specialised Therapeutics, reinforcing our strategic collaboration with Incyte and enabling impactful, clinically relevant dialogue among experts through the presentation of tafasitamab and axatilimab updates.

𝗞𝗲𝘆 𝗔𝗦𝗛 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗲:

𝗧𝗮𝗳𝗮𝘀𝗶𝘁𝗮𝗺𝗮𝗯 – 𝗶𝗻𝗠𝗜𝗡𝗗 𝘀𝘂𝗯𝗴𝗿𝗼𝘂𝗽 𝗮𝗻𝗮𝗹𝘆𝘀𝗲𝘀
• Outcomes by age – Publication 3582
• Outcomes in second-line treatment – Publication 1819
• Preservation of CD19 expression – Publication 5515
• Outcomes in high-risk patients – Publication 5367

𝗔𝘅𝗮𝘁𝗶𝗹𝗶𝗺𝗮𝗯 – 𝗔𝗚𝗔𝗩𝗘 𝟮𝟬𝟭 & 𝗿𝗲𝗹𝗮𝘁𝗲𝗱 𝘀𝘁𝘂𝗱𝗶𝗲𝘀
• Long-term treatment duration & safety – Publication 6010
• Expanded Access Program safety a**lysis – Publication 6008
• Combination with ruxolitinib in newly diagnosed chronic graft-versus-host disease – Publication 6012

2025 has offered opportunities to engage across major international meetings, including , , and . As we look to 2026, we remain committed to supporting clinicians with timely, evidence-based updates for rare cancers and rare diseases.

cGVHD RareCancers SpecialisedTherapeutics

12/06/2025

Follicular lymphoma may be classified as an indolent disease, but our drive to bring access to innovative treatment stays strong and purposeful.

At , our CEO, Medical Lead, and Therapeutic Lead are on the ground, connecting with haematologists and global experts to review emerging data and discuss evolving treatment approaches. Highlights this year include subgroup a**lyses from the inMIND study of tafasitamab and long-term results for axatilimab from AGAVE-201.

New evidence being presented at ASH may shape future clinical practice in follicular lymphoma and chronic graft-versus-host disease, and we’re committed to advancing therapies for rare and complex haematologic conditions.

11/27/2025

It was great to be back at , connecting with clinicians, researchers, and industry partners to advance care for patients with gastrointestinal (GI) cancers across Australia and New Zealand.

We had the opportunity to discuss evolving treatment strategies and translational research, keeping patients at the centre of our conversations.

Specialised Therapeutics continues to grow our GI oncology portfolio, now including retifanlimab (squamous cell a**l cancer) alongside Abraxane® (nab-paclitaxel – pancreatic and GI cancers), Pemazyre® (pemigatinib – cholangiocarcinoma), Qinlock® (ripretinib – gastrointestinal stromal tumours), and Yondelis® (trabectedin – soft tissue sarcomas), reflecting our commitment to supporting healthcare professionals in delivering patient-focused care.

marked our final oncology conference for 2025, reinforcing our dedication to collaboration, scientific exchange, and improving outcomes for patients.

AdvancingCancerCare

11/25/2025

𝗧𝗵𝗲 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝘁𝗲𝗮𝗺 𝗶𝘀 𝗮𝘁 𝗔𝗚𝗜𝗧𝗚 𝟮𝟬𝟮𝟱!

We’re onsite at the GI Cancer Trials (formerly AGITG) Annual Scientific Meeting 2025, connecting with clinicians, researchers, and industry partners to advance care for patients living with gastrointestinal (GI) cancers.

If you’re attending, come say hello and speak with our team about evolving treatment approaches and our expanding GI oncology portfolio.

09/10/2025

The Consumer Comments process invites patients, carers, healthcare professionals, and advocacy groups to share their experiences, helping inform decisions that affect access to life-changing treatments.

Your input can help ensure that decisions reflect what matters most to those affected. Early engagement is key to shaping outcomes that truly make a difference and impact funding decisions.

This is a unique opportunity: four indications from our pipeline are being reviewed simultaneously, giving stakeholders a chance to provide input on multiple treatments at once.

Reimbursement for therapies in the following disease areas will be under consideration by the Pharmaceutical Benefits Advisory Committee (PBAC) at its November 2025 meeting:

• First-Line Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
• Metastatic Squamous Cell Carcinoma of the A**l Ca**l (SCAC)
• Locally Advanced or Metastatic Merkel Cell Carcinoma (MCC)
• Relapsed/Refractory Follicular Lymphoma (R/R FL)

👉 Submit your comment here: https://2cm.es/19ha2

**lCancer

09/07/2025

สวัสดีค่ะ from Bangkok!

Recently, our team at Specialised Therapeutics attended the 18th Breast Cancer Symposium in .

This annual scientific meeting, themed “Practice Changing in Breast Cancer Management,” welcomed around 200 clinicians and international experts to discuss the latest developments in care.

Over three days, our team connected with more than 100 surgeons and specialists, contributing to discussions on evolving treatment strategies and sharing updates from our breast cancer portfolio, while gaining valuable insights into local clinical practice and patient needs.

Our participation reflects Specialised Therapeutics’ growing presence in and our continued commitment to working alongside healthcare professionals to help address unmet needs in oncology.

ขอบคุณค่ะ 🙏 to the organisers and all the clinicians who welcomed us at this important meeting.

07/01/2025

𝗪𝗲 𝗮𝗿𝗲 𝗲𝗻𝗲𝗿𝗴𝗶𝘀𝗲𝗱 𝗯𝘆 𝘁𝗵𝗲 𝗴𝗹𝗼𝗯𝗮𝗹 𝗺𝗼𝗺𝗲𝗻𝘁𝘂𝗺 𝗶𝗻 𝗹𝘆𝗺𝗽𝗵𝗼𝗺𝗮 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗮𝘁 .

Following a dynamic , our team continued the conversation at in Lugano, Switzerland. Gin Chen (Therapeutic Lead, Haematology) and Bhuvana Ramaswamy (Senior Medical Advisor) joined international experts to explore the latest advancements and treatment strategies in lymphoma.

A key highlight was the study presentation by Professor Laurie Sehn (Canada), evaluating Tafasitamab + Lenalidomide + Rituximab in R/R . Just ahead of the session, Professor Sehn announced the regimen has received FDA approval - a significant milestone. We extend our congratulations to our partner Incyte on this achievement.

At Specialised Therapeutics, we continue to prioritise timely access to MINJUVI® ( ) and work towards securing TGA and PBS approval in Australia.

𝗡𝗲𝘅𝘁 𝘀𝘁𝗼𝗽: , where we look forward to reconnecting with the local community.

06/20/2025

We’re proud that 95% of our team at Specialised Therapeutics agrees we’re a Great Place To Work® Australia, placing us among the top performers in the small pharmaceutical category survey.

This recognition truly reflects the experience we live every day:

• A genuine sense of community (rated 100%)
• A strong, supportive team culture (rated 97%)
• And powerful feedback like:
- “You can count on people to cooperate” - 100% agreement
- “People here are willing to give extra to get the job done” - also 100%

At ST, these results are a reflection of our values - : Passion, Integrity, Teamwork, Courage, and Humanity. These principles guide how we work together, support our partners, care for patients, and remain deeply committed to shaping access to innovative therapies that improve lives.

Carlo Montagner, CEO, shares:
“This certification is a testament to the dedication and collaboration of our entire team. We are committed to fostering a workplace where people feel valued, supported, and inspired to make a difference every day.”

Thank you to everyone at ST for helping build a workplace we’re proud of.

Learn more about our certification: https://lnkd.in/g-if4myC

06/16/2025

𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗮𝘁 #𝗘𝗛𝗔2025 𝗶𝗻 𝗠𝗶𝗹𝗮𝗻

Our presence at this year’s European Hematology Association Congress reflects our deepening commitment to advancing access to innovative therapies across the Asia-Pacific region.

CEO Carlo Montagner and Therapeutic Lead Haematology Gin Chen joined Australian and global experts for an energising few days of high-impact scientific sessions, insights, and collaboration.

We were excited to attend several key oral and late-breaking presentations of therapies from our partner, Incyte. These showcased the strength of their pipeline and progress in treating challenging blood-related diseases.

We were also particularly pleased to attend Incyte’s symposium on emerging topics in diffuse large B-cell lymphoma ( ) and follicular lymphoma ( ), which explored real-world treatment of second-line DLBCL and evolving strategies for FL in the 2L+ setting—critical areas for clinicians and patients alike.

It was a pleasure reconnecting with Luis Feliz MD, EMBA, Incyte’s Medical Affairs Lead, and Chairman and CEO Herve Hoppenot, amongst other senior managers, and celebrate the expansion of our partnership, announced last Friday. Our expanded collaboration represents an exciting new chapter and deepens our shared mission to deliver new therapies for rare and hard-to-treat conditions throughout the Asia-Pacific region.

Read the full press release: https://lnkd.in/gsxH9CUH

06/04/2025

Back from feeling energised and inspired.

Our team - CEO Carlo Montagner, Bhuvana Ramaswamy (Senior Medical Advisor), Kurt Sim Yi Hao (SEA Business Manager), and Lily Glick (Therapeutic Lead, Endocrinology & Oncology) - joined thousands of oncology professionals in for one of the most influential medical congresses focused on cancer research.

This year’s return to ASCO was driven by our enthusiasm to reconnect with global partners, engage in high-impact scientific sessions, and attend presentations highlighting key therapies in our pipeline.

• The pivotal IMforte Phase 3 trial of Zepzelca® (lurbinectedin) in combination with Atezolizumab showed improvements in progression-free and overall survival in the first-line maintenance setting for patients with extensive-stage small cell lung cancer (ES-SCLC).

• The POD1UM-303 pivotal study (retifanlimab-dlwr) presented subgroup
a**lyses and exploratory data in Advanced Squamous Cell A**l Carcinoma (SCAC).

• Final results from the POD1UM-201 (retifanlimab-dlwr) trial in Merkel Cell Carcinoma (MCC) were also presented.

We remain deeply committed to shaping access to therapies that make a meaningful difference for patients in , and .

Specialised Therapeutics

03/30/2026

12/09/2025

12/06/2025

11/27/2025

11/25/2025

09/10/2025

09/07/2025

07/01/2025

06/20/2025

06/16/2025

06/04/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category